Company intelligence / Profile preview

Aria CV

Saint Paul, Minnesota, United Statesariacv.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The Gen 2 Aria CV Pulmonary Hypertension System has been successfully implanted in the first patient as part of the ASPIRE PH clinical trial. The system aims to restore pulmonary artery function and reduce right heart workload. Initial results show reduced blood pressure and improved cardiac output post-procedure. The device has received Breakthrough Device Designation from the FDA and an IDE for pilot studies; it remains investigational with ongoing feasibility trials assessing safety, tolerability, and efficacy.

Therapeutic areas: Cardiovascular
Modalities: DeviceImplantable medical device
Industry: Implantable Medical Devices

Partnerships

Ascension St. Vincent Cardiovascular Research Institute

Beyond the preview

Go deeper on Aria CV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aria CV.

Explore the full profile